Key information

🔎 Fund Overview

Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.